This presentation offers an educational overview of next-generation sequencing (NGS) testing for hematologic malignancies, specifically myeloid disorders and multiple myeloma.
- Compare/Contrast usefulness of NGS testing vs. stand-alone single-gene assays.
- Identify recognized testing recommendations—World Health Organization and National Comprehensive Cancer Network.
- Develop cost-effective and clinically relevant algorithms for testing—diagnostic vs. follow-up testing.
Date & Time
Wednesday, August 30 | Noon–1 p.m. CT
Free for all participants
This webinar is designed for any provider who treats patients with hematologic malignancies (e.g., oncologists, hematologists, and physician assistants), pathologists, hematopathologists, cytogeneticists, laboratory directors, genetic counselors, and laboratory technologists and support staff.
David Viswanatha, M.D.
Co-Director of the Molecular Hematology Laboratory
Consultant in the Division of Hematopathology
Associate Professor of Laboratory Medicine and Pathology
Mayo Medical Laboratories is not an applicable manufacturer or applicable group purchasing organization (GPOs per the Centers for Medicare & Medicaid Services (CMS), and this program does not trigger any reporting requirements pursuant to Open Payments (Sunshine Act) legislation.